Successful treatment of juvenile xanthogranuloma using bevacizumab

详细信息    查看全文

• 作者：Noy Ashkenazy ; MS^a ; Christopher R. Henry ; MD^a ; ^{chenry2@med.miami.edu" class="auth_mail} ; Ashkan M. Abbey ; MD^b ; Craig A. McKeown ; MD^a ; Audina M. Berrocal ; MD^a ; Timothy G. Murray ; MD ; MBA^c
• 刊名：Journal of American Association for Pediatric Ophthalmology and Strabismus
• 出版年：June 2014
• 年：2014
• 卷：18
• 期：3
• 页码：295-297
• 全文大小：466 K

文摘

Juvenile xanthogranuloma (JXG) is an uncommon non-Langerhans cell histiocytic disorder that occurs predominantly in infants. Traditional treatment of ocular JXG involves the administration of topical or local corticosteroids. We treated 2 children with JXG refractory to local corticosteroid therapy with off-label intraocular bevacizumab. To our knowledge, this is the first report of successful use of bevacizumab for ocular JXG.